The rationale for adjuvant chemotherapy for high-risk prostate cancer

Elizabeth C. Kent, Maha H A Hussain*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Purpose of review: With the advent of prostate-specific antigen, stage migration has resulted in a shift towards early-stage prostate cancer at diagnosis. Although radical prostatectomy and radical radiotherapy can be curative in organ-confined disease, there remains a significant proportion of early-stage patients who go on to develop progressive, incurable disease. This review will highlight developments in the identification of high-risk patients, and summarize the results of investigations of adjuvant chemotherapy in this setting. Recent findings: The ability to identify patients at high risk of developing progressive disease is improving. Both preoperative and postoperative variables, as well as newer radiographic and molecular tools, can identify at-risk patients who may benefit from adjuvant therapy. Coupled with developments in chemotherapeutic agents for prostate cancer, this provides the rationale for investigating chemotherapy in this setting. Unfortunately, to date, reported trials involving adjuvant chemotherapy in prostate cancer are few, and generally involve small numbers of patients. Some of the studies confirm that certain populations of patients, such as those with node-positive disease, may benefit from systemic therapy. Definitive data, however, will be derived from ongoing randomized trials investigating adjuvant chemotherapy. Summary: Although definitive data regarding systemic chemotherapy in adjuvant therapy are scarce, the results of the available studies, and the increasing accuracy, in delineating the population at risk, have laid the foundation for future and ongoing studies in this area.

Original languageEnglish (US)
Pages (from-to)123-131
Number of pages9
JournalCurrent Opinion in Urology
Issue number2
StatePublished - Mar 2003


  • Adjuvant therapy
  • Chemotherapy
  • Prostate cancer
  • Risk assessment

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'The rationale for adjuvant chemotherapy for high-risk prostate cancer'. Together they form a unique fingerprint.

Cite this